NDA 206276 · Alcon Labs INC
Pataday Once Daily Relief
Olopatadine Hydrochloride · Ophthalmic
Priority reviewLast checked: Nov 19, 2026Latest source record: Apr 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 30, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
63
22 Phase 3, 0 recruiting
FAERS reports
5,332
1,430 serious, 196 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 20, 2026.
Use temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 13, 2020 Supplement 5 · Efficacy LetterLabelReview
- Jan 30, 2015 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
1 products under this application
- PATADAY ONCE DAILY RELIEF · OLOPATADINE HYDROCHLORIDE EQ 0.7% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Olopatadine" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old PatientsPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00578929 · 2,388 participants · Start Sep 2007 · Primary completion Nov 2008
Drug: Olopatadine Hydrochloride Nasal Spray 0.6%; Vehicle · For: Seasonal Allergic Rhinitis
Sites: Kenilworth, Illinois
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)Pivotal-lookingCompleted
ALK-Abelló A/SIndustry
NCT01700192 · 1,482 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: MK-8237 tablets; Placebo tablets and 4 more · For: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
- Safety of PATANASE Nasal Spray in Patients With Perennial Allergic RhinitisPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00789555 · 1,260 participants · Start Nov 2008 · Primary completion Jan 2011
Drug: Olopatadine hydrochloride 0.6% nasal spray (PATANASE) · For: Perennial Allergic Rhinitis
Sites: Fort Worth, Texas
- Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)Pivotal-lookingCompleted
Glenmark Specialty S.A.Industry
NCT02631551 · 1,180 participants · Start Mar 2016 · Primary completion Jul 2016
Drug: GSP 301 NS; Olopatadine HCl NS and 2 more · For: Seasonal Allergic Rhinitis
Sites: Mission Viejo, California; San Diego, California; San Jose, California · 37 sites in all
- Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)Pivotal-lookingCompleted
Glenmark Specialty S.A.Industry
NCT02870205 · 1,176 participants · Start Aug 2016 · Primary completion Jan 2017
Drug: GSP 301 NS; GOM-NS and 2 more · For: Seasonal Allergic Rhinitis (SAR)
Sites: Mission Viejo, California; Orange, California; San Diego, California · 43 sites in all
- To Study GSP 301 in Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Glenmark Pharmaceuticals Ltd. IndiaIndustry
NCT02318303 · 1,111 participants · Start Dec 2014 · Primary completion Feb 2015
Drug: GSP 301-1 NS (QD); GSP 301-2 NS (BID) and 5 more · For: Seasonal Allergic Rhinitis
Sites: Austin, Texas; Kerrville, Texas; New Braunfels, Texas · 10 sites in all
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02478398 · 1,025 participants · Start Jul 20, 2015 · Primary completion Nov 9, 2018
Drug: Short ragweed pollen allergen extract; Placebo and 5 more · For: Rhinitis, Allergic, Seasonal
- Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic ConjunctivitisPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01743027 · 902 participants · Start Jan 2013 · Primary completion Jul 2013
Drug: AL-4943A ophthalmic solution; Olopatadine hydrochloride ophthalmic solution, 0.2% and 2 more · For: Allergic Conjunctivitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure1,934
- drug ineffective543
- eye irritation282
- vision blurred223
- eye discharge175
- eye pain164
- headache161
- ocular hyperaemia136
- eye pruritus135
- nausea129
- diarrhoea121
- fatigue114
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 17 |
| 2009 | 18 |
| 2010 | 26 |
| 2011 | 25 |
| 2012 | 24 |
| 2013 | 30 |
| 2014 | 29 |
| 2015 | 49 |
| 2016 | 82 |
| 2017 | 91 |
| 2018 | 131 |
| 2019 | 191 |
| 2020 | 1,941 |
| 2021 | 380 |
| 2022 | 408 |
| 2023 | 425 |
| 2024 | 431 |
| 2025 | 513 |
| 2026 | 492 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety.
Sil A, Tripathi SK, Chaudhuri A, et al. · J Dermatolog Treat 2013 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.
McLaurin EB, Marsico NP, Ackerman SL, et al. · Adv Ther 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM, Tekelioglu Y, Turk A, et al. · Clin Ther 2005 · Clinical Trial, Comparative Study
- Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis.
Tian HY, Xu C, Liu CJ, et al. · Int Arch Allergy Immunol 2026 · Network Meta-Analysis, Comparative Study
- Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children.
Hardas A, Singh N, Mohanty A, et al. · Eye (Lond) 2022 · Randomized Controlled Trial
- Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis.
Chen R, Zheng D, Zhang Y, et al. · Eur Arch Otorhinolaryngol 2022 · Meta-Analysis, Systematic Review
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.